Compare IDEXX Laboratories, Inc. (IDXX) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Novartis AG — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while Novartis AG trades at $143.75 (market cap $268.57B). The key difference: Novartis AG is far larger — about 6.6× IDEXX Laboratories, Inc.'s market cap, and Novartis AG pays a 3.31% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Novartis AG for 82 Days on average.
| IDXX | NVS | |
|---|---|---|
Market Cap | $40.43B | $268.57B |
Volume | 692,164 | 1,532,573 |
Sector | Health | Health |
52-Week High | $766.68 | $168.62 |
52-Week Low | $504.70 | $121.80 |
Typical Hold Time | 46 Days | 82 Days |
Enterprise Value | $41.32B | $309.89B |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $513.14, up 1.28% with strong fundamentals including 25.03% net income margin and 74.21% ROE. The stock shows bearish technical signals but maintains consistent earnings beats and analyst consensus of $665 price target. Recent acquisition of CoVetAI expands AI capabilities in veterinary workflow intelligence, supporting long-term growth framework.
Outlook remains positive with revenue growth accelerating to $4.3B in 2025 and projected $4.6B in 2026. Key risks include foreign exchange headwinds and weaker U.S. veterinary visits. The 56.5% buy rating from analysts suggests continued confidence in the company's diagnostic innovation pipeline and recurring revenue economics.
NVS trades at $143.11, down 0.12% on the day, with a bearish technical signal and mixed earnings history including a recent Q1 2026 miss. The company maintains strong profitability with a 22.5% net income margin and 30.55% ROE, while recent news highlights a major $7.8B licensing deal with China's Abogen and ongoing investor scrutiny following clinical trial setbacks.
The outlook is cautious; analyst consensus is a Hold with a $146 price target, but risks include pipeline disappointments and M&A execution. Upside hinges on successful drug launches and deal integration, while downside stems from competitive pressures and regulatory challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
